

## Grifols launches its Erytra Eflexis, a powerful blood-typing system, in China

- *New solution marks another Grifols immunohematology milestone in China, where it has been ensuring the safety of the country's blood supply for 25 years*
- *Erytra Eflexis is a fully automated, powerful analyzer that flexibly adapts to variable volumes to perform complex pretransfusion compatibility testing*
- *The rollout in China of the innovative blood-typing system greatly enhances Grifols' leadership in transfusion medicine*

**Barcelona, Spain, April 29, 2024** – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced it has launched its leading blood-typing technology – the fully automated Erytra Eflexis – in the Chinese market following regulatory approval.

The system, with “load-and-go” automation to rapidly perform complex blood-typing analytics, represents a new generation of fully automated blood typing analyzers designed to enhance pretransfusion compatibility testing.

Using Grifols' proprietary DG gel technology, which confirms blood-group compatibility through the presence or absence of different red-blood antigens and antibodies, the smart, flexible, and intuitive Erytra Eflexis optimizes workflow efficiency and improves daily workloads at hospitals' immunohematology laboratories.

It can be tailored to various lab configurations and processing needs with a high level of flexibility and adaptability while providing reliable, timely results. It can also be employed as a standalone solution or in combination with other Grifols instrumentation.

The availability of Erytra Eflexis in China comes 25 years after Grifols introduced its first immunohematology systems in the country. It builds on the existing local portfolio that also includes Procleix automated NAT (nucleic acid test) solutions based on proprietary TMA (transcription-mediated amplification) technology for blood and plasma screening. The company, an established global leader in transfusion medicine, first began doing business in the country in 1983.

“We are committed to fostering localization and further strengthening China's innovative diagnostics ecosystem to benefit patients,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “With the introduction of the highly flexible and efficient Erytra Eflexis in China, Grifols continues to reinforce its leadership in transfusion safety.”

# GRIFOLS

## About Grifols Erytra Eflexis

Erytra Eflexis is a state-of-the-art, mid-sized analyzer that performs pretransfusion compatibility testing. The system allows for high throughput and enables optimized staffing, reduced waste, improved patient care, as well as increased efficiency and accuracy.

## About DG Gel System

The DG Gel system instruments and reagents use the DG Gel card technology to help labs streamline pretransfusion compatibility tests and tailor the extended phenotype profile for each patient's need. DG Gel system reagents include comprehensive DG Gel card profiles, reagent red blood cell options and complete liquid antisera.

To learn more, visit: <https://www.diagnostic.grifols.com/en/dg-gel-system>

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

---

## MEDIA CONTACTS:

### Grifols Press Office

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

## **Investors**

Investors Relations & Sustainability

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Tel. +34 93 571 02 21

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.